Pharmaceuticals

Bi-Specific MAbs Market Outlook Showing Growth Toward $21.83 Billion by 2030

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Bi-Specific MAbS Market During The Forecast Period 2026–2030?

The bi-specific mabs market has shown rapid expansion in recent years. It is projected to grow from $11.64 billion in 2025 to $13.16 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The historical development of this market can be attributed to the approval of first bsabs therapies, the increasing incidence of hematological cancers, the early adoption of monoclonal antibodies, significant investment in oncology r&d, and a rise in hospital-based clinical trials.

The bi-specific mabs market size is projected to experience rapid expansion in the coming years. It is expected to reach $21.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This growth throughout the forecast period can be attributed to advancements in gene and cell therapy integration, the expansion of the bsabs pipeline, increased r&d funding for rare diseases, a rise in precision medicine adoption, and the emergence of novel bsabs delivery platforms. Prominent trends for the forecast period include the expansion of tumor immunotherapy applications, the development of multi-targeted bi-specific antibodies, growth in hemophilia and rare disease treatments, advancements in in vitro and in vivo platforms, and increasing collaborations between pharma and biotech firms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Drivers Are Expected To Influence The Bi-Specific MAbS Market During The Forecast Period?

The expanding occurrence of cancer alongside other chronic ailments is expected to fuel the expansion of the bispecific monoclonal antibodies market throughout the projected timeframe. These antibodies are designed to treat a range of conditions, including various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are deemed more efficacious than traditional monoclonal antibodies (moAbs) because they target multiple (two or more) tumor antigens on cells, thereby impeding cancer advancement. As an illustration, the Cancer Facts & Figures 2023 report, issued by the US-based voluntary health organization American Cancer Society (ACS), indicated that an estimated 609,820 cancer-related deaths are expected in the USA in 2023. Consequently, a growing incidence of chronic conditions, particularly cancer, is foreseen to drive the need for bispecific MAbs for their effective treatment.

What Market Segments Are Evaluated Within The Bi-Specific MAbS Market?

The bi-specific mabs market covered in this report is segmented –

1) By Drug: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Industry Trends Are Redefining The Bi-Specific MAbS Market?

Leading companies in the bi-specific mAbs market are concentrating on technological advancements, such as CD20 x CD3 T-cell engaging bispecific antibodies, to address the increasing need for more potent, ready-to-use immunotherapies in hematological malignancies that provide fixed-duration treatment courses. A CD20 x CD3 bispecific antibody is constructed to position T cells close to B cells through binding CD3 on T cells and CD20 on B cells, thereby stimulating T-cell-mediated eradication of malignant B cells; in contrast to conventional monoclonal antibodies that solely target B cells (or only T-cell checkpoints), this innovative design utilizes immune effector function in a highly specific manner. For instance, in June 2023, Roche AG, a Switzerland-based biopharmaceutical firm, introduced Columvi (glofitamab-gxbm), a CD20xCD3 bispecific T-cell engager. Columvi possesses a unique 2:1 structural format (two CD20-binding domains and one CD3-binding domain), is administered as an approximately 8.5-month fixed-duration therapy, and is intended to deliver lasting responses in individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Its fixed-duration treatment schedule presents the possibility of a treatment-free interval following therapy, setting it apart from continuous treatment methods, and it has demonstrated robust effectiveness in clinical studies with controllable safety.

Who Are The Top Market Participants Influencing The Bi-Specific MAbS Market?

Major companies operating in the bi-specific mabs market are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda Pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Sanofi S.A., Novo Nordisk A/S, Aspen Pharmacare, Baxter International

Read the full bi-specific mabs market report here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Region Is Forecast To Lead The Bi-Specific MAbS Market In Terms Of Market Size?

North America was the largest region in the bi-specific MAbs market in 2025. The regions covered in the bi-specific mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Bi-Specific MAbS Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Bi Specific Mab Market Report 2026

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Anti Cancer Mabs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795